Columbia University has a vibrant innovation and entrepreneurship ecosystem, with a variety of offerings at the University, School, and Department level.
Columbia Entrepreneurship, Innovation, and Design (“Columbia Entrepreneurship”) aims to support, invigorate, accelerate, and motivate the Columbia community’s programs and culture around innovation, creativity, and entrepreneurship. The ecosystem around entrepreneurship at Columbia is vibrant, brilliant, and cutting edge. At the very heart of Columbia Entrepreneurship’s mandate is to find ways to take advantage of the enormous power, vitality, and resources of the entire University so that, indeed, the whole of our energies is much greater than merely the sum of the parts.
Columbia Engineering Entrepreneurship supports students, faculty, and alumni (from SEAS and across the university) at all stages of innovation and entrepreneurship activities.
As a vital part of Columbia's innovative culture, the Department of Biomedical Engineering’s faculty and graduate student inventors are on the cutting-edge of scientific innovation, creating solutions to some of society’s most challenging problems. In the past 5 years, BME researchers have made over 140 new inventions, which led to over 30 new licenses to industry, 20 of which were to new startup companies formed around Columbia innovations.
The Columbia Biomedical Engineering Technology Accelerator (formerly the Columbia-Coulter Translational Research Partnership) aims to catalyze the advancement of biomedical technologies by providing funding, education, resources and mentorship to teams of clinicians, engineers and scientists working to develop solutions to clinical unmet needs, with the ultimate goal of bringing innovative research out of the lab to benefit society.
Co-founders Teresa Cauvel, MS ‘16, BME, and Sona Shah MS ‘16, BME, founded Neopenda to address a massive global health challenge: Too many critically ill newborns are dying from preventable causes in low-resource settings, often times because hospitals are severely understaffed and there is no equipment to help identify a newborn in distress.
Kinnos was founded by Jason Kang,BS ‘16 BME, to protect healthcare workers, patients, and friends and family from infections. Developed and first implemented during the 2014 Ebola crisis in West Africa, Highlight® was created to address the urgent need to improve disinfection for both epidemic response and daily prevention. Our goal is to empower people to protect themselves and others, and to provide society with peace of mind through disinfection you can see.
Co-founded by John O’Neill, PhD ‘17, BME, and University and Mikati Foundation Professor of Biomedical Engineering and Medical Sciences Gordana Vunjak-Novakovic, Xylyx Bio specializes in cell-specific biomaterials. Rather than isolated components or synthetic materials, the Company’s suite of extracellular matrix-derived products provide the most physiological cell environment possible in which to create and deliver effective science-based solutions for the benefit of human life and health.
Co-founded by Nina Tandon, PhD ‘09, BME, MBA ‘12, CBS, and Gordana Vunjak-Novakovic, University and Mikati Foundation Professor of Biomedical Engineering and Medical Sciences, EpiBone, Inc. is a privately-held regenerative medicine company focused on skeletal reconstruction. Sitting at the intersection of biology and engineering, the company harnesses the power of a patient's own cells to create living solutions that become a seamless part of a patient's body. EpiBone is currently developing a pipeline of bone, cartilage, and compound (bone and cartilage) products.
IEOR E4003: Corporate Finance for Engineers
This course is required for all undergraduate students majoring in IEOR. Introduction to the economic evaluation of industrial projects. Economic equivalence and criteria. Deterministic approaches to economic analysis. Multiple projects and constraints. Analysis and choice under risk and uncertainty.
or
The Columbia BiomedX program (formerly the Columbia-Coulter Translational Research Partnership) aims to catalyze the advancement of biomedical technologies by providing funding, education, resources and mentorship to teams of clinicians, engineers and scientists working to develop solutions to clinical unmet needs, with the ultimate goal of bringing innovative research out of the lab to benefit society.
Project support is expected to serve as a bridge to commercial investment, with awards granted to perform specific tasks needed to validate a commercial hypothesis (vs. a scientific hypothesis). You can find a list of past BiomedX awardees here.
BiomedX is part of Columbia's Lab-to-Market Accelerator Network and is run in collaboration with Columbia Technology Ventures. Funding for the BiomedX program has been generously provided by the Yiannis and Jamie Monovoukas BiomedX Fund; The Fu Foundation School of Engineering and Applied Science; Department of Biomedical Engineering; Columbia University Irving Medical Center; Department of Medicine; Department of Medicine, Seymour, Paul and Gloria Milstein Division of Cardiology; Department of Surgery; Department of Orthopedic Surgery; College of Dental Medicine; and the Irving Institute for Clinical and Translational Research.